{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Any event, Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"Any event, Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Any event, Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Any event, Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Any event, Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a clinical investigation patient, temporally associated with the use of a medical product, whether or not considered related to the medicinal product. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack efficacy), abuse or misuse.","groups":[{"description":"Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.","id":"OG000","title":"NY-ESO 1 Group"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The analysis was performed on the total treated cohort (TTC), which included all subjects who received at least one dose of the Antigen-Specific Cancer Immunotherapeutic (ASCI) treatment.","reportingStatus":"POSTED","timeFrame":"During the study treatment period (maximum duration = 49 months).","title":"Number of Patients With Adverse Events (AEs) by Maximum Grade","type":"SECONDARY","unitOfMeasure":"Participants"}